Cboe BZX · UNOVHealthcarePharmaceuticals

Innovator U.S. Equity Ultra Buffer ETF - November financials

$41.36−0.24%
Close Sep 28, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY26
Mar 31
FY25
Mar 31
FY24
Mar 31
FY23
Mar 31
FY22
Mar 31
FY21
Mar 31
FY20
Mar 31
Revenue$35.7M$33.1M$12.0M$48.5K$14.1K$140.9K$526.1K
Gross profit$25.5M$24.3M$7.8M$22.1K-$8.5K$39.9K$218.5K
Gross margin71.4%73.4%65.5%45.4%−60.3%28.3%41.5%
Operating income$3.3M$3.4M$892.3K-$936.7K-$226.7K-$4.3M-$908.6K
Net income$3.6M$3.3M$812.1K-$365.4K$3.2M-$4.4M-$1.2M
Net margin10.2%9.8%6.8%−752.8%22468.7%−3110.8%−228.1%
Diluted EPS$0.01$0.01$0.00$0.00$0.06$-0.08$-0.03
EBITDA$3.8M$3.8M$2.8M-$919.2K-$226.7K-$430.7K-$816.6K
Operating cash flow$1.9M$4.4M$1.2M-$1.0M-$168.1K-$196.7K-$518.6K
Free cash flow$1.0M$3.2M$1.2M-$1.0M-$168.1K—-$518.6K
Diluted shares293.1M303.5M309.7M145.9M53.9M53.9M50.9M

Balance sheet

Period endMar 31Mar 31Mar 31Mar 31Mar 31Mar 31
Cash & equivalents$796.8K$1.5M$697.7K$35.8K$26.9K$16.2K
Short-term investments$1.4M$645.4K$0.00$0.00$0.00—
Total debt$0.00$241.5K$91.2K$809.2K$780.7K$616.4K
Total assets$9.0M$7.1M$3.9M$2.7M$76.9K$64.6K
Total liabilities$1.9M$3.2M$1.6M$1.6M$1.9M$5.1M
Shareholders' equity$7.0M$3.9M$2.2M$1.1M-$1.8M-$5.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology